What can we learn from adherence data in adolescents participating in a clinical trial? by unknown
POSTER PRESENTATION Open Access
What can we learn from adherence data in
adolescents participating in a clinical trial?
Jemma Jay Angela Anderson1,2*, Catherine Leggett3, Jenny Couper1,2, Alexia Peña1,2
From 8th APPES Biennial Scientific Meeting
Darwin, Australia. 29 October – 1 November 2014
Introduction
Treatment adherence during adolescence is challenging.
Limited data exist for the rate of medication adherence
in adolescents.
Aim
To evaluate medication adherence using two different
methods (electronic monitoring system and tablet
count) in adolescents with Type 1 Diabetes (T1D) parti-
cipating in an RCT.
Method
Medication adherence was assessed in 54 T1D adoles-
cents (age 14±2.3y, 26 males) enrolled in a 1 year RCT
to receive metformin or placebo [1].
Adherence was assessed using tablet count and pro-
spective electronic monitoring using Medication Event
Monitoring System caps (MEMS, AARDEX group, LTD
Sion, Switzerland), which recorded episodes of bottle
opening for each participant. These data were then
compared to prescribed doses.
Adequate adherence was defined as ≥ 80% of pre-
scribed doses taken over a defined period. Adherence
was assessed after allowing a 3-month run-in period to
account for dose titration and minimise potential for
reactivity associated with initial adherence monitoring.
Data were reported from 3-6 months (short-term) and
from 6-12 months (long-term).
Results
Adolescents had mean T1D duration 5.9±4.2y, median
HbA1c 8.5 (6.3-11.6)%. 26 used CSII.
MEMS adherence data for short and long-term use
was available for 53 and 48 participants respectively.
Adequate adherence using MEMS was 47% (25/53)
short-term and 35 (17/48) long-term. Median (IQR 25-
75%) adherence was 79 (46.6-88.7%) short-term and 67
(43.4-86.8%) long-term.
Tablet count adherence data for short and long-term
use was available for 35 and 42 participants respectively.
Adequate adherence using tablet count was 63% (22/35)
short-term and 45% (19/42) long-term. Median (IQR
25-75%) was 84 (70.8-90.1%) short-term and 77 (61.7-
86.8%) long-term.
There was no statistically significant difference in
adherence between the two methods used p=0.22
(short-term) and p=0.07 (long-term). Adolescents who
were adherent in the short-term by MEMS were more
likely to have a longer diabetes duration (7.2 vs
4.8 years, p=0.03).
Conclusion
Adolescent adherence to intervention in this clinical
trial was suboptimal as shown by both electronic moni-
toring and tablet count. This finding reinforces the
importance of parental involvement in treatment regi-
mens in this population.
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